# US 11,999,722 B2 · Disubstituted pyrazole compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,999,722 B2
- Document ID: US11999722B2
- Status: Granted
- Kind: B2
- Application number: 17/478,080
- Filed: 2021-09-17
- Published: 2022-01-20
- Granted: 2024-06-04
- Earliest claimed: 2019-06-17
- Assignees: Eli Lilly and Company
- Applicants: Eli Lilly and Company
- Inventors: David Andrew Coates; Timothy Barrett Durham; Richard Duane Johnston; Steven Marc Massey; Patrick Gianpietro Spinazze; Douglas Richard Stack; James Lee Toth
- Web page: https://patentgrep.com/patent/US11999722B2

## CPC

- C07D 401/14: containing three or more hetero rings
- C07D 403/14: containing three or more hetero rings
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 13/12: of the kidneys
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a compound of Formula I. or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.

## Claims

### Claim 1

A method of treating chronic kidney disease in a patient, comprising administering to a patient in need of such treatment an effective amount of a compound of the formula:
wherein
X is N, or C substituted with CN;
R1 is selected from: H,
R2 and R3 are both H, or one is H and the other is OH;
R4, R5, R6, R7 and R9 are independently H or CH3;
R8 is H, CH3, CH2CH2OH, C(═O)CH2NH2, or C(═O)CH3; and
R10 is OH or NH2;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method according to claim 1, wherein R1 is selected from:
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the compound is:
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

The method according to claim 1, wherein X is N, or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The method according to claim 1, wherein X is C substituted with CN, or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the compound is:
or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 6)

The method, according to claim 6, wherein the compound is a succinate salt.